Dedifferentiated Liposarcoma Treatment Market : Get Facts About Business Strategies 2018–2026
Liposarcoma
refers to one of the most commonly diagnosed type of soft tissue
sarcomas. It is a type of cancer that originates from the fat cells
in deep tissues. On the other hand, dedifferentiated Liposarcoma is
the least common subtypes among all types of sarcomas and arises from
a well-differentiated sarcoma. The tumors of dedifferentiated
Liposarcoma are typically present in the retroperitoneal/abdominal
cavity followed by the limbs. The reason for development of these
tumors are still unknown, however, genetic mutations is considered to
be one of the factors in generation of these tumors. The most
commonly employed treatment for dedifferentiated sarcoma includes
complete excision and removal of the tumor by various therapies such
as liposuction and targeted immunotherapy. Dedifferentiated
Liposarcoma does not have any gender predilection, however, is
commonly found in patients over the age of 50 years. The global
dedifferentiated Liposarcoma treatment market is expected to exhibit
a moderate growth rate, which attributes to low incidence of the
disease across the globe. According to the World Health Organization
2016, the incidence rate of well-differentiated Liposarcoma accounts
for 2.5 per million, wherein de-differentiated Liposarcoma accounts
for 18% of the total incidence of Liposarcoma across the globe.
Regional Insights
On the basis of
region, the global dedifferentiated Liposarcoma treatment market by
Coherent Market Insights is segmented into North America, Latin
America, Europe, Asia Pacific, Middle East, and Africa. North America
holds the dominant position in the global dedifferentiated
Liposarcoma treatment market, owing to increasing research and
development of novel therapies and potential drugs for
dedifferentiated Liposarcoma. For instance, the Sarcoma Foundation of
America (SFA) aids sarcoma patients by providing funding for research
to private researchers and conducts education campaigns for patients
suffering from various types of sarcomas.
Furthermore, Asia
Pacific market is expected to gain significant traction in the near
future, owing to increasing research and development of new drugs and
immunotherapies, to combat the disease as well as presence of
significant population suffering from the disease in this region. For
instance, according to the Journal of Blood & Lymph 2013, in
India up to 35% of patients suffering with Sarcoma died due to
dedifferentiated Liposarcoma, wherein the total number of deaths as a
result of sarcoma was reported to be 328 patients in 2012.
Competitive
Analysis
Key players
operating in the global dedifferentiated Liposarcoma treatment market
include Johnson & Johnson Services, Inc., Eli Lily & Company,
Novartis AG, Pfizer, Inc. and Sanofi SA. Major players are focusing
on innovation and development, to maintain their position in the
market and enhance its share. For instance, in July 2017, Karyopharm
Therapeutics, Inc. cleared Phase II clinical trial for Selinexor, an
orally administered inhibitor of CRM1, to treat patients with
unresectable dedifferentiated liposarcoma.
Market Taxonomy:
The chemotherapy
segment is expected to be dominant, owing to widespread availability
of drugs across the world. According to the British Medical Journal,
the European Medical Agency approved the use of 48 cancer drugs for
68 indications in Europe. Moreover, patent expiry is leading to
entrance of large number of generic players in the market, which also
propels growth of chemotherapy segment. However, immunotherapy is
expected to gain marginal traction in the forecast period, owing to
extensive research and development associated with the implementation
of targeted cell therapy and other immunotherapies that have lower
side effects than the chemotherapy. According to Memorial Sloan
Kettering Cancer Center 2015, checkpoint inhibitor based
immunotherapy is being effectively tested against dedifferentiated
Liposarcoma and has potential benefits in treating the disorder.
Ask For Discount
Before Purchasing This Business Report @
On the basis of
treatment type, the global dedifferentiated Liposarcoma treatment
market is segmented into:
Chemotherapy
Immunotherapy
Radiation
Therapy
On the basis of
end user, the global dedifferentiated Liposarcoma treatment market is
segmented into:
Hospitals
Multispecialty
Clinics
Cancer Treatment
& Rehabilitation Centers
About Coherent
Market Insights
Coherent Market
Insights is a prominent market research and consulting firm offering
action-ready syndicated research reports, custom market analysis,
consulting services, and competitive analysis through various
recommendations related to emerging market trends, technologies, and
potential absolute dollar opportunity.
Contact Us
Mr. Shah
Coherent Market
Insights
1001 4th Ave, #3200
Seattle, WA 98154
Tel: +1-206-701-6702
Comments
Post a Comment